Grupo para la caracterización molecular de las neoplasias hematológicas
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublications in collaboration with researchers from Hospital de Gran Canaria Dr. Negrin (31)
2024
-
Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study
Annals of Hematology
-
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461
2023
-
CNL and aCML should be considered as a single entity based on molecular profiles and outcomes
Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)
Journal of Clinical Medicine, Vol. 12, Núm. 20
2022
-
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry
Leukemia Research, Vol. 115
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
Cancer, Vol. 128, Núm. 13, pp. 2441-2448
2021
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
2020
-
Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis
Medicina Clinica, Vol. 155, Núm. 4, pp. 152-158
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2019
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients
Leukemia Research, Vol. 76, pp. 1-10
2018
-
Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia
British Journal of Haematology
-
Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098